• Search
  • Helpdesk
  • Sales contact

Case study

Tackling the specificities of NASH/MASH clinical trials

Integrating PROs into studies on MASH, also known as NASH, is crucial. MASH is a debilitating chronic illness that significantly impairs patients' quality of life, affecting their daily routines, work, and...

Mastering pediatric asthma clinical trials

Asthma clinical trials present several specificities, such as the use of disease-specific health-related quality of life instruments. Asthma clinical research...

Ophthalmology Clinical Trials

Ophthalmic conditions and vision impairment currently affect 2.2 billion people globally: Data collection can be very challenging for patients with...

How Kayentis Helps You Manage The Growing Complexities Of eCOA Trials

We all know clinical trials are more and more complex, involving an increasing number of systems, multiple populations, and an...

Rare Disease case study

Over 90% of rare diseases have no treatment…  There are more than 6,000 known rare diseases... Approximately 80% of them have...

Tackling the complexity of pediatric clinical trials

Despite the evolution in pediatric legislation and a renewed interest in developing therapeutics for pediatric and rare diseases, pediatric clinical...

Big Pharma Case Study

Kayentis has more than twenty years of success stories with Big Pharma, and has been helping Big Pharma mitigate clinical...

Immunology Case Study

Immunology studies present specific challenges: their eCOA build can be complex, site staff must play a key role, and study...

Kayentis & RWS partnering for success

Kayentis (global provider of eCOA and DCT solutions) and RWS (language service provider (LSP) and linguistic validation experts) were selected...

Oncology Case Study

Oncology studies present specific challenges that generate complex eCOA build and management: complex study design, frequent amendments, and long study...

Dermatology Case Study

Kayentis offers extensive expertise in dermatology and a solid experience with several typical PROs, ClinROs and Patient Diaries.With a large...

Kayentis supports the 1st personalized immunotherapy treatment approved by both FDA & EMA

Acute Lymphoblastic or Lymphoid Leukemia (ALL) is a cancer of the lymphocytes that can result in serious complications such as...
Follow us on social media
Subscribe to our newsletter
About the author